Biotech · Private company
GI Innovation, Inc.
Track this companyFree. Adds GI Innovation, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- bevacizumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- doxorubicinPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- eribulinPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- GI-101Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- GI-101APhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- GI-102Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- GI-102Phase 2 · Metastatic Castration-resistant Prostate Cancer (mCRPC)ClinicalTrials.gov · fetched Nov 12, 2026
- GI-102 subcutaneous (SC)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- LenvatinibPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- paclitaxelPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PasritamigPhase 2 · Metastatic Castration-resistant Prostate Cancer (mCRPC)ClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)PHASE1_PHASE2 · RECRUITING · started Oct 12, 2026ClinicalTrials.gov NCT07871435 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)PHASE1_PHASE2 · RECRUITING · started May 30, 2023ClinicalTrials.gov NCT05824975 · fetched Nov 12, 2026
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Aug 2, 2021ClinicalTrials.gov NCT04977453 · fetched Nov 12, 2026